Meta analysis of the intervention of Baduanjin in middle-aged and elderly patients with essential hypertension

Resumo original em inglês

O que aconteceu

We systematically evaluated Baduanjin efficacy for improving blood pressure, lipid metabolism, and heart rate in middle-aged and elderly patients with essential hypertension, explored its physiological mechanisms, and assessed evidence quality using GRADE criteria.

We searched CNKI, PubMed, and Web of Science (January 2010-March 2025) for randomized controlled trials (RCTs). Twenty-four RCTs (1994 participants, aged 35-80 years, interventions: 3-12 months) met inclusion criteria.

O que encontraram

systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), total cholesterol (TC), heart rate (HR). We assessed risk of bias using Cochrane/PEDro tools and performed meta-analysis using random-effects models. Sensitivity analyses excluded studies with high bias risk, non-standard interventions, or inconsistent control groups.

Baduanjin significantly reduced SBP by 8.3 mmHg (3 months), 11.4 mmHg (6 months), and 5.4 mmHg (12 months); DBP by 3.9 mmHg (3 months), 6.2 mmHg (6 months), and 4.1 mmHg (12 months). It improved TG (SMD = -0.34 [95 % CI: -0.49, -0.19]), TC (SMD = -0.92 [-1.49, -0.34]; high heterogeneity), and HR (SMD = -1.07 [-1.76, -0.38]). GRADE rated evidence quality as moderate (most BP outcomes), low (TG), and very low (TC), primarily due to methodological limitations.

Por que isso importa

Baduanjin is an effective, low-cost adjunct intervention for essential hypertension, particularly reducing blood pressure within 3-6 months. We recommend implementing 3-6-month Baduanjin programs (5-6 sessions/week) in clinical practice. Benefits on lipid metabolism and heart rate require confirmation via higher-quality trials. Future research should standardize protocols and explore mechanisms.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.